一、产品概述
CS-2638 是来自Absin品牌的高品质产品,适用于科研实验领域。
更多产品描述请查看优宁维旗下爱必信官网(https://www.absin.cn/sitravatinib/abs818855.html?mk_channel=chemicalbook)
二、产品信息
| 货号 | abs818855 |
| SKU货号 | abs818855-10mg |
| 品牌 | Absin |
| 中文名称 | CS-2638 |
| 英文名称 | Sitravatinib |
| CAS号 | 1123837-84-2 |
| 纯度 | 98% |
| 分子量 | 629.68 |
| 可溶性 | DMSO : ≥ 32 mg/mL (50.82 mM) |
| 外观 | Off-white solid |
| 抗原名称 | DDR2;EPHA3;Axl;Mer;VEGFR3 (FLT4) |
商品描述
Sitravatinib (MGCD516; MG516) is an orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT , FLT3, DDR2, DDR1, TRKA, TRKB, respectively.
In vitro(体外研究)
MGCD516 (Sitravatinib), is an oral, potent small molecule inhibitor of a closely related spectrum of RTKs including RET, the split RTKs (VEGFR, PDGFR and KIT), TRK family, DDR2, MET and AXL. MGCD516 treatment resulted in significant blockade of phosphorylation of potential driver RTKs and induced potent anti-proliferative effects in vitro.
In vivo(体内研究)
Sitravatinib has demonstrated antitumor activity in nonclinical cancer models harboring genetic alterations of sitravatinib targets, including rearrangement of RET, NTRK, or CHR4q12 amplification. MGCD516 treatment of tumor xenografts in vivo resulted in significant suppression of tumor growth. Efficacy of MGCD516 was superior to imatinib and crizotinib, two other well-studied multi-kinase inhibitors with overlapping target specificities, both in vitro and in vivo.
三、背景
四、制备和贮存
| 保存方式 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
五、产品特点
- 品质保证:经过严格的质量控制,确保产品的高品质和稳定性。
- 高纯度:纯度达到<p>98%</p>。
六、注意事项
- 本产品仅供科学研究使用,不可用于临床诊断或治疗。
- 请在通风良好的环境下操作,佩戴适当的个人防护装备。
- 如不慎接触皮肤或眼睛,请立即用大量清水冲洗并就医。